help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on February 6, 2007
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-2554
A more recent version of this article appeared on April 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
92/4/1564    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Costa-Guda, J.
Right arrow Articles by Arnold, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Costa-Guda, J.
Right arrow Articles by Arnold, A.

Submitted on November 21, 2006
Accepted on January 25, 2007

Absence of stabilizing mutations of {beta}-catenin encoded by CTNNB1 exon 3 in a large series of sporadic parathyroid adenomas

Jessica Costa-Guda and Andrew Arnold*

Center for Molecular Medicine and Division of Endocrinology and Metabolism, University of Connecticut School of Medicine, Farmington, CT, USA

* To whom correspondence should be addressed. E-mail: molecularmedicine{at}uchc.edu.

Context: The molecular mechanisms underlying the pathogenesis of sporadic parathyroid adenomas are incompletely understood. Dysfunction of the Wnt signalling pathway is an established pathogenetic contributor to human tumorigenesis and recently, the role of stabilizing mutations in {beta}-catenin, a cause of abnormal Wnt signaling, has been examined in parathyroid tumors with conflicting results.

Objective: The objective of the present study was to determine the frequency of stabilizing mutations in exon 3 of CTNNB1, encoding {beta}-catenin, in a large series of parathyroid adenomas.

Patients and Design: Ninety-seven sporadic parathyroid adenomas were examined for mutations in exon 3 of CTNNB1 by direct DNA sequencing.

Results: No mutations were identified in any of the adenomas.

Conclusions: The absence of stabilizing mutations of {beta}-catenin, including the previously reported S37A, encoded in CTNNB1 exon 3 among 97 tumors suggests that such mutations contribute rarely if at all to the development of sporadic parathyroid adenomas. A primary role for abnormal Wnt signaling in parathyroid tumor formation remains to be established.


Key words: hyperparathyroidism • PTH • Wnt signaling • endocrine neoplasia




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
W. F. Simonds
Ruling Out a Suspect: the Role of {beta}-Catenin Mutation in Benign Parathyroid Neoplasia
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1235 - 1236.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society